Sign Up Today and Learn More About Orasis Pharmaceuticals Stock
Invest in or calculate the value of your shares in Orasis Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Orasis Pharmaceuticals Stock (ORAP)
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company that develops eye drops for the treatment of presbyopia.
About Orasis Pharmaceuticals Stock
Founded
2015
Headquarters
Ponte Vedra, FL, US
Industries
Software, Artificial Intelligence, Data and Analytics
Orasis Pharmaceuticals Press Mentions
Stay in the know about the latest news on Orasis Pharmaceuticals
Ophthalmic pharmaceutical compositions and uses relating thereto
patents • Feb 08, 2025
Presbyopia Market Trends and Forecast to 2034 | Research by DelveInsight
einpresswire • Jan 08, 2025
Ophthalmic Packaging Market Size Expected to Reach USD 15.89 Bn by 2034
globenewswire • Dec 06, 2024
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight
prnewswire • Nov 15, 2024
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight
prnewswire • Nov 15, 2024
Orasis Pharmaceuticals Management
Leadership team at Orasis Pharmaceuticals
Board of Directors
Masafuyu Tanaka
CEO
Elad Kedar
Join now and verify your accreditation status to gain access to:
- Orasis Pharmaceuticals Current Valuation
- Orasis Pharmaceuticals Stock Price
- Orasis Pharmaceuticals Management
- Available deals in Orasis Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Orasis Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Orasis Pharmaceuticals Revenue and Financials
- Orasis Pharmaceuticals Highlights
- Orasis Pharmaceuticals Business Model
- Orasis Pharmaceuticals Risk Factors
- Orasis Pharmaceuticals Research Report from SACRA Research
Trading Orasis Pharmaceuticals Stock
How to invest in Orasis Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Orasis Pharmaceuticals through EquityZen funds. These investments are made available by existing Orasis Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Orasis Pharmaceuticals stock?
Shareholders can sell their Orasis Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
